Detection of malignant mesothelioma in asbestos-exposed individuals: The potential role of soluble mesothelin-related protein

Hematology/Oncology Clinics of North America

Volumn 19, Issue 6, 2005, Pages 1025-1040

  Creaney, Jenette ^a   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BIOLOGICAL MARKER; CA 125 ANTIGEN; CYTOKERATIN 19 FRAGMENT; FERRITIN; GLYCOPROTEIN; HYALURONIC ACID; IMMUNOTOXIN; MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; MESOTHELIN IMMUNOTOXIN; MESOTHELIN RELATED PROTEIN; PROTEIN; TISSUE POLYPEPTIDE ANTIGEN; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; HUMAN; LUNG RESECTION; MALIGNANT MESOTHELIOMA; OVARY CANCER; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; VALIDATION PROCESS;

ASBESTOS; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; MALE; MASS SCREENING; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 28444452270     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.09.007     Document Type: Review

References (62)

1. A.W. Musk, and N.H. de Klerk Epidemiology of malignant mesothelioma in Australia Lung Cancer 45 Suppl 1 2004 S21 S23
2. K. Antman, H. Pass, and P. Schiff Benign and malignant mesothelioma V.T. DeVita S. Hellman S. Rosenberg Cancer: principles and practice of oncology 2001 Lippincott-Raven Philadelphia 1943 1970
3. N.J. Vogelzang Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 14 2003 2636 2644
4. D. Whitaker The cytology of malignant mesothelioma Cytopathology 11 3 2000 139 151
5. N.G. Ordonez The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma Am J Surg Pathol 27 8 2003 1031 1051
6. National Occupational Health and Safety Commission The incidence of mesothelioma in Australia 1997 to 1999: Australian Mesothelioma Register Report 2002 National Occupational Health and Safety Commission Canberra (Australia)
7. J. Leigh, and T. Driscoll Malignant mesothelioma in Australia, 1945-2002 Int J Occup Environ Health 9 3 2003 206 217
8. J.H. Lange Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003 Am J Epidemiol 160 8 2004 823
9. F. Benard Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography Chest 114 3 1998 713 722
10. A.W. Musk Wittenoom, Western Australia: a modern industrial disaster Am J Ind Med 21 5 1992 735 747
11. S.J. Chapman Benign asbestos pleural diseases Curr Opin Pulm Med 9 4 2003 266 271
12. N. Shah, and A. Williams Surviving the asbestos epidemic 2001 Price Waterhouse Coopers London
13. S. Carroll Asbestos litigation costs and compensation: an interim report 2002 Rank Organisation Publications Santa Monica (CA)
14. J.G. Elmore Screening for breast cancer JAMA 293 10 2005 1245 1256
15. M.Q. Bromer, and D.S. Weinberg Screening for colorectal cancer: now and the near future Semin Oncol 32 1 2005 3 10
16. C. Boutin Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma Cancer 74 9 1994 2460 2467
17. D.J. Sugarbaker Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients J Thorac Cardiovasc Surg 117 1 1999 54 63 [discussion: 63-5]
18. T. Treasure, and A. Sedrakyan Pleural mesothelioma: little evidence, still time to do trials Lancet 364 9440 2004 1183 1185
19. G. Hillerdal The Swedish experience with asbestos: history of use, diseases, legislation, and compensation Int J Occup Environ Health 10 2 2004 154 158
20. M. Robinson, and J. Wiggins Statement on malignant mesothelioma in the UK Thorax 57 2 2002 187
21. M. Tiitola Computed tomography screening for lung cancer in asbestos-exposed workers Lung Cancer 35 1 2002 17 22
22. L.A. Peipins Radiographic abnormalities and exposure to asbestos-contaminated vermiculite in the community of Libby, Montana, USA Environ Health Perspect 111 14 2003 1753 1759
23. U. Haberkorn Positron emission tomography in the diagnosis of mesothelioma Lung Cancer 45 Suppl 1 2004 S73 S76
24. W. Ebert Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE Anticancer Res 17 4B 1997 2875 2878
25. A. Thylen, J. Wallin, and G. Martensson Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma Cancer 86 10 1999 2000 2005
26. M. Hedman Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma Anticancer Res 23 1B 2003 531 536
27. V. Barak Clinical utility of cytokeratins as tumor markers Clin Biochem 37 7 2004 529 540
28. Y.C. Lee, B.S. Knox, and J.E. Garrett Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions Aust N Z J Med 29 6 1999 765 769
29. J.M. Bonfrer Cyfra 21-1 and TPA as markers in malignant mesothelioma Anticancer Res 17 4B 1997 2971 2973
30. R.C. Bast Jr CA 125: the past and the future Int J Biol Markers 13 4 1998 179 187
31. V.R. Zurawski Jr Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer Obstet Gynecol 69 4 1987 606 611
32. I.J. Jacobs Screening for ovarian cancer: a pilot randomised controlled trial Lancet 353 9160 1999 1207 1210
33. M. Kebapci CT findings and serum CA 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature Eur Radiol 13 12 2003 2620 2626
34. H. Simsek, A. Kadayifci, and E. Okan Importance of serum CA 125 levels in malignant peritoneal mesothelioma Tumour Biol 17 1 1996 1 4
35. J. Hernandez, and I.M. Thompson Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker Cancer 101 5 2004 894 904
36. H.I. Meissner Promoting cancer screening: learning from experience Cancer 101 5 Suppl 2004 1107 1117
37. M. Sullivan Pepe Phases of biomarker development for early detection of cancer J Natl Cancer Inst 93 14 2001 1054 1061
38. B.W. Robinson Mesothelin-family proteins and diagnosis of mesothelioma Lancet 362 9396 2003 1612 1616
39. K. Chang, and I. Pastan Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers Proc Natl Acad Sci U S A 93 1 1996 136 140
40. A. Rump, Y. Morikawa, and M. Tanaka Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion J Biol Chem 279 10 2004 9190 9198 [Epub 2003 Dec 15]
41. N. Yamaguchi A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5 J Biol Chem 269 2 1994 805 808
42. T. Kojima Molecular cloning and expression of megakaryocyte potentiating factor cDNA J Biol Chem 270 37 1995 21984 21990
43. N. Scholler Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma Proc Natl Acad Sci U S A 96 20 1999 11531 11536
44. Z.E. Muminova, T.V. Strong, and D.R. Shaw Characterization of human mesothelin transcripts in ovarian and pancreatic cancer BMC Cancer 4 1 2004 19
45. R. Hassan, T. Bera, and I. Pastan Mesothelin: a new target for immunotherapy Clin Cancer Res 10 12 Pt 1 2004 3937 3942
46. K. Chang, I. Pastan, and M.C. Willingham Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium Int J Cancer 50 3 1992 373 381
47. K. Chang Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium Cancer Res 52 1 1992 181 186
48. D. Urwin, and R.A. Lake Structure of the mesothelin/MPF gene and characterization of its promoter Mol Cell Biol Res Commun 3 1 2000 26 32
49. T.K. Bera, and I. Pastan Mesothelin is not required for normal mouse development or reproduction Mol Cell Biol 20 8 2000 2902 2906
50. C.D. Hough Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer Cancer Res 60 22 2000 6281 6287
51. K. Wang Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray Gene 229 1-2 1999 101 108
52. P. Argani Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 12 2001 3862 3868
53. Y. Hippo Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes Cancer Res 61 3 2001 889 895
54. H.F. Frierson Jr Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas Hum Pathol 34 6 2003 605 609
55. K. Chang Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma Am J Surg Pathol 16 3 1992 259 268
56. N.G. Ordonez Application of mesothelin immunostaining in tumor diagnosis Am J Surg Pathol 27 11 2003 1418 1428
57. M. Miettinen, and M. Sarlomo-Rikala Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura Am J Surg Pathol 27 2 2003 150 158
58. A.M. Thomas Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients J Exp Med 200 3 2004 297 306
59. Pass H. Surgery for mesothelioma at the NCI and KCI: going somewhere very slowly. Presented at the 7th Meeting of the International Mesothelioma Interest Group. Brescia (Italy), June 24-26, 2004
60. S.J. Skates Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers Cancer 76 10 Suppl 1995 2004 2010
61. N. Urban Ovarian cancer screening Hematol Oncol Clin North Am 17 4 2003 989 1005
62. I. Jacobs Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography BMJ 306 6884 1993 1030 1034